Calf Augmentation in Manaus BR
This procedure offers a solution for those people that have underdeveloped calves or wish to augment them. The idea is to shape and size the calves by surgical insertion of implants. The implants are made of soft silicon and they come in different shapes and sizes. Before the operation your legs will be measured to select a proper implant for your needs. There is an alternative to implants. Calf augmentation can also be performed by liposuction of fat from other body parts and injecting it into the calves. This method is not suitable for people with no extra fat to be removed. Another problem is fat absorption that eventually occurs, sometimes creating not symmetric calves. Men and women can benefit from this procedure. Men usually want to increase the muscle bulk, giving them more masculine look and women wish to get more symmetrical appearance of their legs. This procedure also may help to correct some congenital defects, those include polio, spina bifida and clubfoot, all this conditions may be associated with undeveloped calves.
This procedure can be done with local or general anesthesia, and it usually lasts for an hour. During the operation the patient is laying on their back. A cut is made in the concavity behind the knee, then the skin is gently separated and a space is created. The implant is inserted above the muscles. After one leg is done the doctor performs the same on the other one. After the symmetry is confirmed the surgeon closes the cuts with stitches.
Every operation has its ricks. This one includes bleeding, infection and sometimes implants shrinkage and asymmetry.
After the surgery you may feel some degree of pain. Your doctor'll subscribe you for painkillers. At the first two days you'll be asked to raise your legs whenever you are sitting, this to reduce swelling. Afterwards, the bandages are removed and you are encouraged to walk more intensively to train your calve muscles. For about two weeks you'll fell like you're calves is been through excessive workout. Swelling and bruising also may appear, they are only temporary and will improve with time. You'll be able to go back to work after 7-10 days. You'll get detailed instructions from you're surgeon regarding the activities you should avoid, for example long walking, weight lifting and running. Usually, most of the patients are able to return to their daily activities after 4-6 weeks.
More Manaus info...
Manaus Eat
Local cuisine is rich and varied and can be found in many restaurant and stalls. You may try tapioquinha, a glutinous pancake made from manioc starch, usually buttered and filled with tucum? palm fruit and farmer’s cheese. Or tacac?, an Amazon local soup. Or pamonha, made from green corn and coconut milk boiled in corn husks. Or bolo de macaxeira, a tasty but heavy glutinous translucent oily cake made from manioc. Or sugar cane juice, a favorite drink among locals. The region is also known for its exotic fruits like creamy white capua?? and iron-rich a?a?.
-
Manaus By bus
Due to road conditions, there is very little (if any) long-distance bus service originating from major cities in Brazil. There are daily buses to Boa Vista in the north and to destinations in Venezuela. The bus from Caracas in Venezula takes about 36 hours, but it is air-conditioned, has comfortable reclining seats and a toilet.
-
Plastic Surgery News...
- Reps. Anna Eshoo (D-Calif.) and Joe Barton (R-Texas) on Thursday introduced a bill that would allow FDA to approve generic versions of biotechnology medications, CongressDaily reports. The legislation would provide brand-name biotech companies with at least 12 years, and possibly an additional 2.
Context No antidiabetic regimen has demonstrated the ability to reduce progression of coronary atherosclerosis. Commonly used oral glucose-lowering agents include sulfonylureas, which are insulin secretagogues, and thiazolidinediones, which are insulin sensitizers.
Objective To compare the effects of an insulin sensitizer, pioglitazone, with an insulin secretagogue, glimepiride, on the progression of coronary atherosclerosis in patients with type 2 diabetes.
Design, Setting, and Participants Double-blind, randomized, multicenter trial at 97 academic and community hospitals in North and South America (enrollment August 2003-March 2006) in 543 patients with coronary disease and type 2 diabetes.
Interventions A total of 543 patients underwent coronary intravascular ultrasonography and were randomized to receive glimepiride, 1 to 4 mg, or pioglitazone, 15 to 45 mg, for 18 months with titration to maximum dosage, if tolerated. Atherosclerosis progression was measured by repeat intravascular ultrasonography examination in 360 patients at study completion.
Main Outcome Measure Change in percent atheroma volume (PAV) from baseline to study completion.
Results Least squares mean PAV increased 0.73% (95% CI, 0.33% to 1.12%) with glimepiride and decreased 0.16% (95% CI, –0.57% to 0.25%) with pioglitazone(P = .002). An alternative analysis imputing values for noncompleters based on baseline characteristics showed an increase in PAV of 0.64% (95% CI, 0.23% to 1.05%) for glimepiride and a decrease of 0.06% (–0.47% to 0.35%) for pioglitazone (between-group P = .02). Mean (SD) baseline HbA1c levels were 7.4% (1.0%) in both groups and declined during treatment an average 0.55% (95% CI, –0.68% to –0.42%) with pioglitazone and 0.36% (95% CI, –0.48% to –0.24%) with glimepiride (between-group P = .03). In the pioglitazone group, compared with glimepiride, high-density lipoprotein levels increased 5.7 mg/dL (95% CI, 4.4 to 7.0 mg/dL; 16.0%) vs 0.9 mg/dL (95% CI, –0.3 to 2.1 mg/dL; 4.1%), and median triglyceride levels decreased 16.3 mg/dL (95% CI, –27.7 to –11.0 mg/dL; 15.3%) vs an increase of 3.3 mg/dL (95% CI, –10.7 to 11.7 mg/dL; 0.6%) (P < .001 for both comparisons). Median fasting insulin levels decreased with pioglitazone and increased with glimepiride (P < .001). Hypoglycemia was more common in the glimepiride group and edema, fractures, and decreased hemoglobin levels occurred more frequently in the pioglitazone group.
Conclusion In patients with type 2 diabetes and coronary artery disease, treatment with pioglitazone resulted in a significantly lower rate of progression of coronary atherosclerosis compared with glimepiride.
Trial Registration clinicaltrials.gov Identifier: NCT00225277
Published online March 31, 2008 (doi:10.1001/jama.299.13.1561).